{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:44Z","timestamp":1792790564443,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Paula and Rodger Riney foundation, Multiple Myeloma Research Fund at Massachusetts General Hospital","id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Japan Society for the Promotion of Science, Multiple Myeloma Research Fund at Massachusetts General Hospital","id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01190-9","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:42:51Z","timestamp":1734936171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0166-7727","authenticated-orcid":false,"given":"Rie","family":"Nakamoto-Matsubara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Horick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8821-2689","authenticated-orcid":false,"given":"Ryan S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4350-9240","authenticated-orcid":false,"given":"Rajib","family":"Shome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyosumi","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Panaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keertik","family":"Fulzele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2797-956X","authenticated-orcid":false,"given":"Farah","family":"Rexha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3868-9267","authenticated-orcid":false,"given":"Andrew R.","family":"Branagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cirstea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-7133","authenticated-orcid":false,"given":"David T.","family":"Scadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-1275","authenticated-orcid":false,"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"1190_CR1","unstructured":"E.Campo NLH, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumors of haematopoietic and lymphoid tissues. (IARC Press; 2016)."},{"key":"1190_CR2","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1002\/cncr.34134","volume":"128","author":"EK O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Hu BY, Laubach JP, et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer 2022;128:1996\u20132004.","journal-title":"Cancer"},{"key":"1190_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia 2020;34:1\u201320.","journal-title":"Leukemia"},{"key":"1190_CR4","doi-asserted-by":"crossref","unstructured":"Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A, et al. Management of relapsed-refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice. Cancers. 2023;15:2160.","DOI":"10.3390\/cancers15072160"},{"key":"1190_CR5","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.7863\/ultra.32.10.1777","volume":"32","author":"JP Pintoffl","year":"2013","unstructured":"Pintoffl JP, Weisel K, Schulze M, Maksimovic O, Claussen CD, Kramer U, et al. Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data. J Ultrasound Med 2013;32:1777\u201388.","journal-title":"J Ultrasound Med"},{"key":"1190_CR6","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017;18:e206\u2013e17.","journal-title":"Lancet Oncol"},{"key":"1190_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2019.219139","volume":"105","author":"V Montefusco","year":"2020","unstructured":"Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, et al. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica 2020;105:193\u2013200.","journal-title":"Haematologica"},{"key":"1190_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blade","year":"2022","unstructured":"Blade J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 2022;12:45.","journal-title":"Blood Cancer J"},{"key":"1190_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosinol","year":"2021","unstructured":"Rosinol L, Beksac M, Zamagni E, Van de Donk N, Anderson KC, Badros A, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 2021;194:496\u2013507.","journal-title":"Br J Haematol"},{"key":"1190_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1600-0609.2005.00531.x","volume":"75","author":"E Terpos","year":"2005","unstructured":"Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005;75:376\u201383.","journal-title":"Eur J Haematol"},{"key":"1190_CR11","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 2012;97:1761\u20137.","journal-title":"Haematologica"},{"key":"1190_CR12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/leu.2011.29","volume":"25","author":"KD Short","year":"2011","unstructured":"Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25:906\u20138.","journal-title":"Leukemia"},{"key":"1190_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/10428190802657751","volume":"50","author":"P Wu","year":"2009","unstructured":"Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma 2009;50:230\u20135.","journal-title":"Leuk Lymphoma"},{"key":"1190_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21:325\u201330.","journal-title":"Ann Oncol"},{"key":"1190_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720571","volume":"12","author":"H Deng","year":"2021","unstructured":"Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, et al. Efficacy of humanized Anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease. Front Immunol 2021;12:720571.","journal-title":"Front Immunol"},{"key":"1190_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood-2004-03-0833","volume":"105","author":"T Rasmussen","year":"2005","unstructured":"Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005;105:317\u201323.","journal-title":"Blood"},{"key":"1190_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.35","volume":"6","author":"SJ de Haart","year":"2016","unstructured":"de Haart SJ, Willems SM, Mutis T, Koudijs MJ, van Blokland MT, Lokhorst HM, et al. Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses. Blood Cancer J 2016;6:e426.","journal-title":"Blood Cancer J"},{"key":"1190_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","volume":"3","author":"M Andrulis","year":"2013","unstructured":"Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013;3:862\u20139.","journal-title":"Cancer Discov"},{"key":"1190_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/PAS.0000000000001459","volume":"44","author":"Y Liu","year":"2020","unstructured":"Liu Y, Jelloul F, Zhang Y, Bhavsar T, Ho C, Rao M, et al. Genetic basis of extramedullary plasmablastic transformation of multiple myeloma. Am J Surg Pathol 2020;44:838\u201348.","journal-title":"Am J Surg Pathol"},{"key":"1190_CR20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kortum","year":"2016","unstructured":"Kortum KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood 2016;128:1226\u201333.","journal-title":"Blood"},{"key":"1190_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2141.2004.05199.x","volume":"127","author":"H Chang","year":"2004","unstructured":"Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004;127:280\u20134.","journal-title":"Br J Haematol"},{"key":"1190_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/787809","volume":"2015","author":"X Qu","year":"2015","unstructured":"Qu X, Chen L, Qiu H, Lu H, Wu H, Qiu H, et al. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed Res Int 2015;2015:787809.","journal-title":"Biomed Res Int"},{"key":"1190_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.12223","volume":"161","author":"L Billecke","year":"2013","unstructured":"Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol 2013;161:87\u201394.","journal-title":"Br J Haematol"},{"key":"1190_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11680-1","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun 2019;10:3835.","journal-title":"Nat Commun"},{"key":"1190_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467\u201372.","journal-title":"Nature"},{"key":"1190_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ebiom.2014.11.008","volume":"2","author":"E O\u2019Donnell","year":"2015","unstructured":"O\u2019Donnell E, Mahindra A, Yee AJ, Nardi V, Birrer N, Horick N, et al. Clinical grade \u201cSNaPshot\u201d genetic mutation profiling in multiple myeloma. EBioMedicine 2015;2:71\u20133.","journal-title":"EBioMedicine"},{"key":"1190_CR27","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 2015;33:3911\u201320.","journal-title":"J Clin Oncol"},{"key":"1190_CR28","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","volume":"111","author":"H Ludwig","year":"2008","unstructured":"Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008;111:4039\u201347.","journal-title":"Blood"},{"key":"1190_CR29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","volume":"120","author":"JB Egan","year":"2012","unstructured":"Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012;120:1060\u20136.","journal-title":"Blood"},{"key":"1190_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.36","volume":"6","author":"J Xu","year":"2017","unstructured":"Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, et al. Molecular signaling in multiple myeloma: association of RAS\/RAF mutations and MEK\/ERK pathway activation. Oncogenesis 2017;6:e337.","journal-title":"Oncogenesis"},{"key":"1190_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/oncolo\/oyac226","volume":"28","author":"AJ Frank","year":"2023","unstructured":"Frank AJ, Dagogo-Jack I, Dobre IA, Tait S, Schumacher L, Fintelmann FJ, et al. Management of lung cancer in the patient with interstitial lung disease. Oncologist 2023;28:12\u201322.","journal-title":"Oncologist"},{"key":"1190_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","volume":"25","author":"AG Stephen","year":"2014","unstructured":"Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging Ras back in the ring. Cancer Cell 2014;25:272\u201381.","journal-title":"Cancer Cell"},{"key":"1190_CR33","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/bjc.2016.182","volume":"115","author":"S Renaud","year":"2016","unstructured":"Renaud S, Seitlinger J, Falcoz PE, Schaeffer M, Voegeli AC, Legrain M, et al. Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery. Br J Cancer 2016;115:346\u201353.","journal-title":"Br J Cancer"},{"key":"1190_CR34","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973\u20137.","journal-title":"Nature"},{"key":"1190_CR35","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","volume":"88","author":"P Liu","year":"1996","unstructured":"Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996;88:2699\u2013706.","journal-title":"Blood"},{"key":"1190_CR36","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/bjh.13258","volume":"169","author":"D Smith","year":"2015","unstructured":"Smith D, Armenteros E, Percy L, Kumar M, Lach A, Herledan G, et al. RAS mutation status and bortezomib therapy for relapsed multiple myeloma. Br J Haematol 2015;169:905\u20138.","journal-title":"Br J Haematol"},{"key":"1190_CR37","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/leu.2008.142","volume":"22","author":"WJ Chng","year":"2008","unstructured":"Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008;22:2280\u20134.","journal-title":"Leukemia"},{"key":"1190_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41416-020-01090-2","volume":"124","author":"R Rabbie","year":"2021","unstructured":"Rabbie R, Ferguson P, Wong K, Couturier DL, Moran U, Turner C, et al. The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. Br J Cancer 2021;124:156\u201360.","journal-title":"Br J Cancer"},{"key":"1190_CR39","first-page":"4252","volume":"130","author":"MR Paul","year":"2020","unstructured":"Paul MR, Pan TC, Pant DK, Shih NN, Chen Y, Harvey KL, et al. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest 2020;130:4252\u201365.","journal-title":"J Clin Invest"},{"key":"1190_CR40","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067\u201376.","journal-title":"Blood"},{"key":"1190_CR41","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neo.2017.12.005","volume":"20","author":"Z Shajani-Yi","year":"2018","unstructured":"Shajani-Yi Z, de Abreu FB, Peterson JD, Tsongalis GJ. Frequency of somatic TP53 mutations in combination with known pathogenic mutations in colon adenocarcinoma, non-small cell lung carcinoma, and gliomas as identified by next-generation sequencing. Neoplasia 2018;20:256\u201362.","journal-title":"Neoplasia"},{"key":"1190_CR42","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci Usa 2003;100:8424\u20139.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"1190_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/ng0593-42","volume":"4","author":"D Dittmer","year":"1993","unstructured":"Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nat Genet 1993;4:42\u20136.","journal-title":"Nat Genet"},{"key":"1190_CR44","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","volume":"119","author":"GA Lang","year":"2004","unstructured":"Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861\u201372.","journal-title":"Cell"},{"key":"1190_CR45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ccell.2018.07.004","volume":"34","author":"R Schulz-Heddergott","year":"2018","unstructured":"Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi LC, Bohnenberger H, et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell 2018;34:298\u2013314.e7.","journal-title":"Cancer Cell"},{"key":"1190_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03224-w","volume":"9","author":"T Cooks","year":"2018","unstructured":"Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris J, et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun 2018;9:771.","journal-title":"Nat Commun"},{"key":"1190_CR47","doi-asserted-by":"crossref","unstructured":"Flynt E, Bisht K, Sridharan V, Ortiz M, Towfic F, Thakurta A. Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma. Cells. 2020;9:287.","DOI":"10.3390\/cells9020287"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01190-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01190-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01190-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T07:02:58Z","timestamp":1734937378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01190-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1190"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01190-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Massachusetts General Hospital (15-190). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations. Informed consent was obtained from all individual participants in this analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"224"}}